Mously Haytham, Shah Nischay, Zuzek Zachary, Alshaghdali Ibrahim, Karim Adham, Jaswaney Rahul, Filby Steven J, Simon Daniel I, Shishehbor Mehdi H, Forouzandeh Farshad
Harrington Heart and Vascular Institute and Case Western Reserve University Cleveland, OH.
US Cardiol. 2021 Jul 14;15:e13. doi: 10.15420/usc.2021.05. eCollection 2021.
In patients presenting with ST-elevation MI, prompt primary coronary intervention is the preferred treatment modality. Several studies have described improved outcomes in patients with door-to-balloon (D2B) and symptom onset-to-balloon (OTB) times of less than 2 hours, but the specific implications of the coronavirus disease 2019 (COVID-19) pandemic on D2B and OTB times are not well-known. This review aims to evaluate the impact of COVID-19 on D2B time and elucidate both the factors that delay D2B time and strategies to improve D2B time in the contemporary era. The search was directed to identify articles discussing the significance of D2B times before and during COVID-19, from the initialization of the database to December 1, 2020. The majority of studies found that onset-of-symptom to hospital arrival time increased in the COVID-19 era, whereas D2B time and mortality were unchanged in some studies and increased in others.
对于ST段抬高型心肌梗死患者,及时进行直接冠状动脉介入治疗是首选的治疗方式。多项研究表明,门球时间(D2B)和症状发作至球囊扩张时间(OTB)少于2小时的患者预后较好,但2019冠状病毒病(COVID-19)大流行对D2B和OTB时间的具体影响尚不清楚。本综述旨在评估COVID-19对D2B时间的影响,并阐明当代延迟D2B时间的因素以及改善D2B时间的策略。检索旨在识别从数据库建立至2020年12月1日期间讨论COVID-19之前和期间D2B时间意义的文章。大多数研究发现,在COVID-19时代,症状发作至入院时间增加,而在一些研究中D2B时间和死亡率未变,在另一些研究中则增加。